Q`Apel Medical Inc. news
Nationally there is a trend moving towards radial artery access versus femoral artery access for endovascular procedures and Q’Apel Medical is leading the way.
Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, announced today the launch of the Armadillo Radial Access System, the latest application of the SelectFlex™ technology and part of the SelectFlex&t
Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, is pleased to announce and welcome Thomas Berryman as Chief Financial Officer. Tom has extensive experience in bringing venture funded medical technology companies from initial startup through product commercialization, revenue growth and exit. Tom is founder of Privy, the maker of Finess®, a novel FDA-cleared
New 35,000 square foot Facility will support the company’s growth and OUS expansion
Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, announced today that it will relocate its existing headquarters into a new building at 4245 Technology Dr, Fremont, CA, 94538. The 35,000 square foot facility accommodates current and future growth and will enhance employees&rsqu
Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, is pleased to announce and welcome Jodie Fam as Vice President and General Manager, International. Jodie will be responsible for the leadership and development of International Sales for Q’Apel. Jodie brings more than 20 years of medical device industry experience. She has a solid track record in building global and geo
Q’Apel Medical, Inc., an innovative neurovascular company specializing in developing and commercializing novel access device technology for vascular interventions, announced today it has raised $22 Million in Series C funding. The round included River Cities Capital, Soleus Capital and incumbent investor, Research Corporation Technologies (RCT). Scott Huennekens, former Chairman, CEO and President of Verb Surgical, and Carter McNabb, Managing Director, River Cities Capital will join the